MOSHE TALPAZ MD
Prescription History 1801972773
Internal Medicine - Medical Oncology in Ann Arbor, MI
Medicare Part D Prescription History
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MOSHE TALPAZ MD, an active Medical Oncology specialist practicing in Ann Arbor, MI. Our medical registry currently tracks 11 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 666 documented patient claims. Among these therapy options, the most frequently utilized medication is Hydroxyurea, which accounts for 187 claims alone. Use the table below to sort by claims, cost, or utilization compared with the state average; select any medication for its full profile.
| Medication | Prescriptions (2023)Rx (2023) | Avg Cost per FillCost / Fill | Vs. Other MI PrescribersVs. MI Avg |
|---|---|---|---|
| JakafiRuxolitinib Phosphate | 187 | $15,319.77 | ▲ More than typical |
About Jakafi: This medication is used to treat certain bone marrow disorders (myelofibrosis, polycythemia vera). Show more ▾ It works by blocking your body from producing substances called growth factors. Growth factors cause cells to grow and divide, and cause the blood cell and spleen problems found in these disorders. Ruxolitinib belongs to a class of drugs known as kinase inhibitors. Though not a cure for these disorders, ruxolitinib may help with some of the symptoms, including abdominal discomfort, pain under left ribs, early feelings of fullness from meals, night sweats, itching, and bone/muscle pain. Ruxolitinib is also used to treat a certain problem that may occur after certain stem cell or bone marrow transplants (graft versus host disease). It works by weakening your body's defense system (immune system). In 2023, this provider wrote 187 Medicare prescriptions for Jakafi, about 6 times the volume of the typical Michigan prescriber of this medication (31). Medicare paid an average of $15,319.77 per fill, versus $15,051.43 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average MI prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 187 30-Day Fills standardized to 30-day supplies 5,549 Days of Medication total across all patients in 2023 | |||
| Hydroxyurea | 187 | $38.52 | ▲ More than typical |
About Hydroxyurea: This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Show more ▾ Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas). An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. In 2023, this provider wrote 187 Medicare prescriptions for Hydroxyurea, about 4.9 times the volume of the typical Michigan prescriber of this medication (38). Medicare paid an average of $38.52 per fill, versus $38.40 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average MI prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 323.6 30-Day Fills standardized to 30-day supplies 9,542 Days of Medication total across all patients in 2023 | |||
| BosulifBosutinib | 65 | $9,193.26▼ below MI avg | ▲ More than typical |
About Bosulif: Bosutinib is used to treat a certain type of blood cancer (chronic myelogenous leukemia-CML). Show more ▾ It works by slowing or stopping the growth of cancer cells. In 2023, this provider wrote 65 Medicare prescriptions for Bosulif, about 2.8 times the volume of the typical Michigan prescriber of this medication (23). Medicare paid an average of $9,193.26 per fill, versus $12,852.56 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average MI prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the MI average for this medication. 65 30-Day Fills standardized to 30-day supplies 1,950 Days of Medication total across all patients in 2023 | |||
| PegasysPeginterferon Alfa-2a | 52 | $2,846.27▼ below MI avg | ▲ More than typical |
About Pegasys: Peginterferon alfa-2a is used alone or in combination with other medications to treat chronic hepatitis B and chronic hepatitis C, viral infections of the liver. Show more ▾ It works by decreasing the amount of hepatitis virus in the body and helps your body's natural defense (immune system) fight the infection. Chronic hepatitis infection can lead to serious liver damage (cirrhosis) and liver cancer. It is not known if peginterferon can cure hepatitis B or hepatitis C infections or can prevent you from passing the virus to others. Practice safer sex (such as the use of latex condoms) to lower the risk of passing the virus to others. In 2023, this provider wrote 52 Medicare prescriptions for Pegasys, about 2.6 times the volume of the typical Michigan prescriber of this medication (20). Medicare paid an average of $2,846.27 per fill, versus $3,514.79 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average MI prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the MI average for this medication. 52 30-Day Fills standardized to 30-day supplies 1,358 Days of Medication total across all patients in 2023 | |||
| Imatinib Mesylate | 36 | $189.87▼ below MI avg | ▲ More than typical |
About Imatinib Mesylate: This medication is used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic/myeloproliferative diseases). Show more ▾ It works by slowing or stopping the growth of cancer cells. Imatinib may also be used to treat certain immune system disorders (such as aggressive systemic mastocytosis, hypereosinophilic syndrome). A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors. In 2023, this provider wrote 36 Medicare prescriptions for Imatinib Mesylate, about 1.5 times the volume of the typical Michigan prescriber of this medication (24). Medicare paid an average of $189.87 per fill, versus $2,841.21 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average MI prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the MI average for this medication. 36 30-Day Fills standardized to 30-day supplies 1,076 Days of Medication total across all patients in 2023 | |||
| SprycelDasatinib | 29 | $6,948.01▼ below MI avg | ▲ More than typical |
About Sprycel: This medication is used to treat certain types of cancer (chronic myeloid leukemia-CML, acute lymphoblastic leukemia-ALL). Show more ▾ It works by slowing or stopping the growth of cancer cells. A pyrimidine and thiazole derived ANTINEOPLASTIC AGENT and PROTEIN KINASE INHIBITOR of BCR-ABL KINASE. It is used in the treatment of patients with CHRONIC MYELOID LEUKEMIA who are resistant or intolerant to IMATINIB. In 2023, this provider wrote 29 Medicare prescriptions for Sprycel, about 1.5 times the volume of the typical Michigan prescriber of this medication (20). Medicare paid an average of $6,948.01 per fill, versus $11,973.26 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average MI prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the MI average for this medication. 29 30-Day Fills standardized to 30-day supplies 842 Days of Medication total across all patients in 2023 | |||
| ScemblixAsciminib Hydrochloride | 27 | $32,991.21 | – No State Data |
About Scemblix: Asciminib is used to treat a certain type of cancer (chronic myeloid leukemia-CML). Show more ▾ Asciminib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. In 2023, this provider wrote 27 Medicare prescriptions for Scemblix. Medicare paid an average of $32,991.21 per fill. No state comparison is available for this medication. How often this provider prescribes it No state benchmark is available for this medication. What Medicare paid per fill $32,991.21 Cost per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 27 30-Day Fills standardized to 30-day supplies 726 Days of Medication total across all patients in 2023 | |||
| TasignaNilotinib Hcl | 27 | $4,874.63▼ below MI avg | ▲ More than typical |
About Tasigna: Nilotinib is used to treat a certain type of blood cancer (chronic myelogenous leukemia-CML). Show more ▾ It works by slowing or stopping the growth of cancer cells. In 2023, this provider wrote 27 Medicare prescriptions for Tasigna, about 1.8 times the volume of the typical Michigan prescriber of this medication (15). Medicare paid an average of $4,874.63 per fill, versus $14,349.21 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average MI prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the MI average for this medication. 27 30-Day Fills standardized to 30-day supplies 756 Days of Medication total across all patients in 2023 | |||
| Anagrelide Hcl | 22 | $168.27▼ below MI avg | ▲ More than typical |
About Anagrelide Hcl: Anagrelide is used to treat a certain blood disorder (thrombocythemia), which is caused by your bone marrow making too many platelets. Show more ▾ Platelets are a blood cell that the body uses to form blood clots. Too many platelets can cause problems with your circulation, including unwanted blood clots and bleeding problems. This drug reduces the number of platelets in the bloodstream by blocking their production. In 2023, this provider wrote 22 Medicare prescriptions for Anagrelide Hcl, about 1.3 times the volume of the typical Michigan prescriber of this medication (17). Medicare paid an average of $168.27 per fill, versus $278.18 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average MI prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the MI average for this medication. 43.7 30-Day Fills standardized to 30-day supplies 1,249 Days of Medication total across all patients in 2023 | |||
| Allopurinol | 19 | $25.83 | ▼ Less than typical |
About Allopurinol: Allopurinol is used to treat gout and certain types of kidney stones. Show more ▾ It is also used to prevent increased uric acid levels in patients receiving cancer chemotherapy. These patients can have increased uric acid levels due to release of uric acid from the dying cancer cells. Allopurinol works by reducing the amount of uric acid made by the body. Increased uric acid levels can cause gout and kidney problems. A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms. In 2023, this provider wrote 19 Medicare prescriptions for Allopurinol, about a third of the volume of the typical Michigan prescriber of this medication (46). Medicare paid an average of $25.83 per fill, versus $14.29 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average MI prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 57 30-Day Fills standardized to 30-day supplies 1,710 Days of Medication total across all patients in 2023 | |||
| Danazol | 15 | $463.10 | ≈ Typical |
About Danazol: This medication is used in women to treat pelvic pain and infertility due to a certain disorder (endometriosis) and also to treat breast pain/tenderness/nodules due to a certain breast condition (fibrocystic breast disease). Show more ▾ It is also used in both men and women to prevent swelling of the abdomen/arms/legs/face/airway due to a certain congenital disease (hereditary angioedema). Danazol is an androgen similar to testosterone. For the treatment of endometriosis and fibrocystic breast disease, it works by decreasing the amount of hormones made by the ovaries. These hormones usually make the conditions worse. For the treatment of angioedema, danazol helps to increase the amount of a certain protein in your body's defense system (immune system). A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. In 2023, this provider wrote 15 Medicare prescriptions for Danazol, about the same volume as the typical Michigan prescriber of this medication (15). Medicare paid an average of $463.10 per fill, versus $403.94 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average MI prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 24 30-Day Fills standardized to 30-day supplies 720 Days of Medication total across all patients in 2023 | |||
About this data. The prescription history for MOSHE TALPAZ MD is compiled from the Centers for Medicare & Medicaid Services (CMS) Medicare Part D Prescriber Public Use File for calendar year 2023, the most recent federal release. Figures cover prescriptions filled for Medicare Part D beneficiaries only; prescriptions under private insurance, Medicaid, or self-pay plans are not included. Because prescribing decisions are generally consistent across coverage types, this record offers a useful view of the overall Medical Oncology prescribing approach at this Ann Arbor, MI practice.
Reading the costs. Drug costs are gross amounts paid to pharmacies under Part D, including both plan and beneficiary payments. They are not the price a patient pays at the pharmacy counter. Medications with fewer than 11 claims are excluded from the federal source data, and state comparisons use the average volume among MI prescribers of the same medication. Always confirm current medications and costs directly with the provider and your plan.
